SG11201900692WA - Donepezil transdermal delivery system - Google Patents

Donepezil transdermal delivery system

Info

Publication number
SG11201900692WA
SG11201900692WA SG11201900692WA SG11201900692WA SG11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA SG 11201900692W A SG11201900692W A SG 11201900692WA
Authority
SG
Singapore
Prior art keywords
international
donepezil
california
transdermal delivery
july
Prior art date
Application number
SG11201900692WA
Other languages
English (en)
Inventor
Eun Soo Lee
Amit K Jain
Parminder Singh
Original Assignee
Corium Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corium Int Inc filed Critical Corium Int Inc
Publication of SG11201900692WA publication Critical patent/SG11201900692WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201900692WA 2016-07-27 2017-07-26 Donepezil transdermal delivery system SG11201900692WA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662367542P 2016-07-27 2016-07-27
US201662367502P 2016-07-27 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US201762444763P 2017-01-10 2017-01-10
US201762444745P 2017-01-10 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US201762504408P 2017-05-10 2017-05-10
US201762504391P 2017-05-10 2017-05-10
PCT/US2017/044050 WO2018022817A1 (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Publications (1)

Publication Number Publication Date
SG11201900692WA true SG11201900692WA (en) 2019-02-27

Family

ID=59523314

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900692WA SG11201900692WA (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system

Country Status (10)

Country Link
US (13) US9993466B2 (https=)
EP (3) EP3490558A1 (https=)
JP (6) JP7071330B2 (https=)
KR (9) KR20230097203A (https=)
CN (5) CN116270551A (https=)
AU (7) AU2017301928B2 (https=)
CA (2) CA3032044C (https=)
MX (2) MX394249B (https=)
SG (1) SG11201900692WA (https=)
WO (3) WO2018022817A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105499A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
WO2017083920A1 (en) * 2015-11-18 2017-05-26 Commonwealth Scientific And Industrial Research Organisation Rice grain with thickened aleurone
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
US20190029971A1 (en) * 2017-07-26 2019-01-31 Corium International, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
BR112022007369A2 (pt) * 2019-10-24 2022-07-05 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico para a administração transdérmica de fingolimode
EP4066829A4 (en) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. METHOD FOR IMPROVING THE HOLDING POWER OF AN ADHESIVE LAYER IN A ROPINIROL-CONTAINING TRANSDERMAL PATCH AND ROPINIROL-CONTAINING TRANSDERMAL PATCH WITH IMPROVED HOLDING POWER
WO2021127092A1 (en) * 2019-12-18 2021-06-24 Pioneer Hi-Bred International, Inc. Compositions and methods for improving grain yield in plants
EP4135673A4 (en) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
WO2023283103A1 (en) * 2021-07-08 2023-01-12 Monsanto Technology Llc Novel insect inhibitory proteins
EP4462992A4 (en) * 2022-01-12 2025-12-24 Inari Agriculture Tech Inc REDUCED HEIGHT CORN
CN121816173A (zh) * 2023-11-16 2026-04-07 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (https=) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
MX9100277A (es) 1990-07-23 1992-02-28 Alza Corp Dispositivo osmotico oral para aplicar nicotina
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
WO1995028914A1 (en) * 1994-04-21 1995-11-02 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
CA2198390C (en) 1994-09-14 2009-08-11 James E. Garbe Matrix for transdermal drug delivery
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
WO1996019205A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
WO1996040087A2 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
CA2264687C (en) 1996-10-24 2006-04-25 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
NZ524940A (en) * 2000-11-06 2003-08-29 Samyang Corp A multilayered sandwich transdermal drug delivery system with improved water absorbability and adhesion properties
JP4057418B2 (ja) * 2000-11-07 2008-03-05 久光製薬株式会社 経皮吸収型製剤
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
ES2331302T3 (es) 2001-05-01 2009-12-29 A.V. Topchiev Institute Of Petrochemical Synthesis Composiciones de hidrogel.
WO2003015713A2 (en) 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
DK1423100T3 (da) 2001-09-04 2007-05-29 Trommsdorff Arzneimittel Plaster indeholdende sertaconazol til behandling af negles dysfunktioner og lidelser
WO2003032960A1 (en) * 2001-10-17 2003-04-24 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption preparations
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
US7273619B2 (en) * 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US20050244485A1 (en) * 2003-10-14 2005-11-03 Tsung-Min Hsu Transdermal administration of hydrophilic drugs using a basic permeation enhancer composition
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
EP1691848B1 (en) 2003-10-23 2012-08-22 TRANS1, Inc. Tools and tool kits for performing minimally invasive procedures on the spine
CA2546395A1 (en) 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1715853A4 (en) 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
US20080038328A1 (en) 2004-05-28 2008-02-14 Naruhito Higo Pasting Preparation
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1807033B1 (en) 2004-10-08 2016-07-20 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2006076562A1 (en) 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20080138388A1 (en) * 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
DK2001671T3 (da) * 2006-03-28 2010-08-09 Amcor Flexibles Transpac B V B Halogenfri flerlagsfilm, som er impermeabel for aromaforbindelser
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
MY149152A (en) 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
EP2638906A1 (en) 2006-12-01 2013-09-18 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
RU2452474C2 (ru) * 2006-12-01 2012-06-10 Нитто Денко Корпорейшн Стабилизированная адгезивная композиция, содержащая донепезил
US20100062045A1 (en) 2006-12-01 2010-03-11 Nitto Denko Corporation Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
US8246978B2 (en) 2007-07-10 2012-08-21 Agile Therapeutics, Inc. Dermal delivery device with reduced loss of its volatile components
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
DE102008013701A1 (de) 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
EP2111857A1 (de) * 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (es) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
WO2010083035A2 (en) * 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
KR101325104B1 (ko) 2009-09-16 2013-11-07 주식회사 삼양바이오팜 경피 투여 제형 및 그 제조 방법
BR112012011334A2 (pt) * 2009-10-21 2020-08-25 Teikoku Seiyaku Co., Ltd. formulação transdermicamente absorvível contendo donepezil
CN102048678A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
HUE025446T2 (en) * 2009-12-30 2016-04-28 Novartis Ag Melt extruded nicotine thin strips
US20100178307A1 (en) 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP5615898B2 (ja) * 2010-02-24 2014-10-29 久光製薬株式会社 貼付剤
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2564848B1 (en) 2010-04-28 2015-09-02 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
TR201818754T4 (tr) 2010-07-29 2019-01-21 Allergan Inc Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
EP2627323A4 (en) 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
AU2011331511C1 (en) 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
CN103384533A (zh) * 2010-12-29 2013-11-06 法玛费尔姆有限责任公司 双氯芬酸二乙铵的改进透皮渗透的药用贴剂
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (ja) * 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) * 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
WO2015031552A1 (en) * 2013-08-30 2015-03-05 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CN105611917A (zh) * 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
CN105722502A (zh) * 2013-11-17 2016-06-29 株式会社梅德瑞科思 经皮吸收胶体型液体制剂
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) * 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
CA2951706A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
EP3169318B1 (en) * 2014-07-18 2020-04-01 Buzzz Pharmaceuticals Limited Abuse deterrent opiod/opiod-antagonist transdermal patch
JP6577795B2 (ja) 2014-09-03 2019-09-18 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
CN107106510A (zh) 2014-12-18 2017-08-29 Icure药品株式会社 含有多奈哌齐为有效成分的经皮吸收制剂
AU2015380301B2 (en) 2015-01-28 2020-04-23 Dnx Biotech, Llc Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life
WO2016209982A1 (en) 2015-06-22 2016-12-29 Corium International, Inc. Transdermal adhesive composition comprising a poorly soluble therapeutic agent
KR102005201B1 (ko) 2015-07-27 2019-07-29 히사미쓰 세이야꾸 가부시키가이샤 아세나핀 함유 첩부제의 제조 방법
US10966936B2 (en) * 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CN105693556A (zh) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
WO2018022814A1 (en) * 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
US20190029971A1 (en) 2017-07-26 2019-01-31 Corium International, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores

Also Published As

Publication number Publication date
US20190247320A1 (en) 2019-08-15
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01
CN109789105B (zh) 2022-12-27
KR20230109782A (ko) 2023-07-20
CN116270551A (zh) 2023-06-23
JP7071330B2 (ja) 2022-05-18
CA3032148A1 (en) 2018-02-01
US20180028462A1 (en) 2018-02-01
KR102406528B1 (ko) 2022-06-08
KR102545649B1 (ko) 2023-06-22
WO2018022815A2 (en) 2018-02-01
JP2019523270A (ja) 2019-08-22
US20210015761A1 (en) 2021-01-21
US20240156747A1 (en) 2024-05-16
US10300025B2 (en) 2019-05-28
KR20220082929A (ko) 2022-06-17
MX394249B (es) 2025-03-24
KR102406482B1 (ko) 2022-06-08
AU2025205205A1 (en) 2025-07-24
KR102555208B1 (ko) 2023-07-17
EP3490558A1 (en) 2019-06-05
EP3490540A1 (en) 2019-06-05
CN116966166A (zh) 2023-10-31
JP2019525932A (ja) 2019-09-12
KR20190035801A (ko) 2019-04-03
AU2023203616A1 (en) 2023-07-06
US10307379B2 (en) 2019-06-04
KR20220082928A (ko) 2022-06-17
AU2023204240A1 (en) 2023-07-27
AU2017302307A1 (en) 2019-02-14
AU2023203618A1 (en) 2023-07-06
CN109789105A (zh) 2019-05-21
AU2023203618B2 (en) 2025-09-18
JP7153010B2 (ja) 2022-10-13
JP2019523268A (ja) 2019-08-22
CA3031945A1 (en) 2018-02-01
MX2019001103A (es) 2019-09-27
CN109789133A (zh) 2019-05-21
EP3490541A2 (en) 2019-06-05
KR20230098349A (ko) 2023-07-03
US20190247321A1 (en) 2019-08-15
JP7251033B2 (ja) 2023-04-04
RU2019105279A3 (https=) 2020-12-23
CA3032044C (en) 2024-10-01
US20180028663A1 (en) 2018-02-01
JP2022121629A (ja) 2022-08-19
US9993466B2 (en) 2018-06-12
WO2018022815A3 (en) 2018-03-08
US20220016045A1 (en) 2022-01-20
AU2017301928B2 (en) 2023-04-06
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
KR20190032512A (ko) 2019-03-27
JP2022140751A (ja) 2022-09-27
US20250325496A1 (en) 2025-10-23
RU2019105279A (ru) 2020-08-27
JP2022093707A (ja) 2022-06-23
US20180235901A1 (en) 2018-08-23
AU2017302306A1 (en) 2019-02-14
KR20230097203A (ko) 2023-06-30
CN109789106B (zh) 2023-06-27
US20180028463A1 (en) 2018-02-01
WO2018022817A1 (en) 2018-02-01
US20250375396A1 (en) 2025-12-11
MX2022006681A (es) 2022-07-11
KR102545643B1 (ko) 2023-06-21
CA3031945C (en) 2025-09-23
KR20190034601A (ko) 2019-04-02
KR102406536B1 (ko) 2022-06-08
US11103463B2 (en) 2021-08-31
EP3490541B1 (en) 2025-07-09
CN109789106A (zh) 2019-05-21
US20180028512A1 (en) 2018-02-01
WO2018022816A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
SG11201900692WA (en) Donepezil transdermal delivery system
SG11201900712SA (en) Memantine transdermal delivery systems
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201906222WA (en) Jak1 selective inhibitors
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201811559WA (en) Cancer treatment combinations
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811760VA (en) Oral dosage form with drug composition, barrier layer and drug layer
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders